Filing summary
Important entity and period mismatch: The supplied filing is Health Sciences Acquisitions Corporation 2’s (HSAC2) Form 10-K for the fiscal year ended December 31, 2020, not an Orchestra Biomed Holdings, Inc. filing. HSAC2 was a blank-check SPAC, not an operating biopharmaceutical company. The reporting period began at incorporation on May 25, 2020; the filing provides no Orchestra Biomed financial results.
Business context and reporting period
HSAC2 was formed to pursue a business combination, with an intended focus on healthcare innovation, including biopharma and medical technology companies in North America or Europe. It had not identified a target or begun substantive operations by year-end. Its shares began trading on Nasdaq under HSAQ in August 2020. The filing was signed March 9, 2021.
Financial results and position
| Metric | Reported amount or status |
|---|---|
| Operating revenue | None; the company expected no operating revenue before a business combination. |
| Net loss | $173,542 from inception through December 31, 2020. |
| Expenses | $179,986 total operating expenses: $129,986 general and administrative expenses and $50,000 related-party administrative fees. |
| Trust investment income | $6,444 net gain on investments held in the trust account. |
| Operating cash flow | $(258,508) used in operating activities. |
| Cash and working capital | $2,026,822 cash and approximately $2.0 million working capital at year-end; prepaid expenses were $122,478. |
| Trust account | $160,006,444 at year-end, invested in short-term U.S. Treasury securities or qualifying Treasury money-market funds. |
| Debt and obligations | No working-capital loans outstanding. The $300,000 sponsor note was repaid in August 2020. A $5.6 million deferred underwriting commission is payable only if a business combination closes. |
| Equity and redemption shares | 15,143,678 shares, recorded as temporary equity subject to possible redemption at $10.00 per share; reported shareholders’ equity was $5,000,008. |
HSAC2 raised $160.0 million in its August 2020 IPO and $6.0 million in a concurrent sponsor private placement. Cash flows from financing activities were $162,285,330, while $160.0 million was deposited in the trust account. No prior-year comparable operating period is presented because the company was incorporated in May 2020.
Changes, outlook, risks, and unusual items
- Outlook: Management believed working capital and borrowing capacity would meet needs through the earlier of a business combination or one year from the filing. No operating revenue, earnings, or margin guidance was provided.
- Combination deadline: HSAC2 had until August 6, 2022 to complete a business combination; otherwise, it would wind up and distribute trust funds to public shareholders, subject to creditor claims and related procedures.
- Transaction terms: A target generally had to have fair market value of at least 80% of trust assets, excluding specified items. The company also required at least $5,000,001 in net tangible assets upon closing. Public-share redemptions could reduce funds available for a transaction.
- Sponsor arrangements: The sponsor agreed to purchase $25 million of HSAC2 shares or equivalent target-company securities before, at, or after a business combination, subject to the agreement’s terms. Sponsor-affiliated entities received a $10,000 monthly administrative fee; $40,000 was accrued at year-end.
- Risk and uncertainty: Management said the specific impact of COVID-19 was not readily determinable; the financial statements included no related adjustments. The trust account could also face creditor claims, and the sponsor’s ability to satisfy its indemnity obligations was not assured.
- Governance and controls: Management concluded disclosure controls were effective. The filing did not include management’s internal-control assessment because of the transition period for newly public companies, nor an auditor attestation on internal controls. The independent auditor gave an unqualified opinion on the financial statements.
- Materiality of results: The filing describes a pre-combination SPAC, so its cash, trust assets, expenses, and redemption mechanics—not operating-company revenue or product performance—are the principal financial considerations.
Most important facts to verify
- Confirm the intended issuer: this document identifies HSAC2, not Orchestra Biomed Holdings, Inc.
- Verify the filing period and status date: fiscal year ended December 31, 2020, with the filing signed March 9, 2021.
- Check subsequent filings for any business combination, liquidation, deadline extension, or change in sponsor purchase commitments.
- Verify current trust-account balance, public-share redemptions, and any liabilities or creditor claims before assessing funds available to a transaction.
- Review the full financial statements and related-party disclosures for the deferred underwriting commission, sponsor fees, and redemption classification.